Navigation Links
Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema

to leave their jobs and one patient in five takes prolonged sick leave resulting in high socio-economic and individual patient burden.

About Alitretinoin Alitretinoin is an investigational drug being developed in Phase III clinical trials by Basilea as a novel treatment for severe refractory Chronic Hand Eczema (CHE), a complex disease for which no effective treatment options are currently available. Alitretinoin has been shown to be effective in Phase II and Phase III clinical studies in patients with severe refractory CHE.

In a phase II double-blind international multi-center placebo controlled trial of 319 patients with moderate and severe chronic hand eczema refractory to topical treatment, alitretinoin was clinically effective in 29% to 53 % of patients depending on the dose administered. Alitretinoin was generally well tolerated with dose dependent headache observed as the most common side effect.

Basilea's first pivotal phase III international multi-center placebo-controlled BACH trial (Benefit of Alitretinoin in Chronic Hand eczema) showed that alitretinoin was effective in patients suffering from severe refractory CHE, as determined by the endpoint of clear and almost clear hands.

This randomized double-blind phase III pivotal study was the largest therapeutic trial ever performed in chronic hand eczema with 1,032 patients whose severe chronic disease was unresponsive to topical steroids. The patients were randomized either to a once-daily dose of 30mg or 10mg of alitretinoin, or placebo for a treatment duration of up to 24 weeks. Alitretinoin's efficacy was significantly superior to placebo in both the high and the low dose regimen. In the 30mg group 48% of patients and in the 10 mg group 28% of patients reached the primary endpoint. In this study alitretinoin was again generally well tolerated with dose dependent headache and blood lipid elevations as the most commonly observed side effects.

Alitretinoin is a teratogen
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Efficacy and Safety Profile of Basileas Alitretinoin for Severe Refractory Chronic Hand Eczema Confirmed by Data Shown at European Dermatology Congress
2. Scientific Results Presented At ECCMID Demonstrate Well- Differentiated Profile of Basileas Two Phase III Anti- infective Compounds
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
(Date:5/29/2015)... Eli Lilly and Company (NYSE: LLY ... Healthcare Conference on Tuesday, June 9, 2015. Jeffrey ... Health, will participate in a fireside chat at 2:20 ... audio webcast will be available on the "Webcasts & ... . A replay of the fireside chat will be ...
(Date:5/29/2015)... Va. , May 29, 2015 LifeNet ... its total hiring for 2015 to more than 160 ... by increased demand for LifeNet Health,s innovative bio-implants, which ... allowing more patients to be served. It also is ... biomedical industry. "The growth and success of ...
(Date:5/29/2015)... Mass. , May 29, 2015  Haemonetics Corporation ... Davies , Chief Operating Officer, will present at the ... York on June 23 rd , 2015 ... may access Mr. Davies, presentation live via webcast at: ... Haemonetics (NYSE: HAE ) is a global healthcare ...
Breaking Medicine Technology:Lilly to Participate in Goldman Sachs Global Healthcare Conference 2LifeNet Health to add more than 160 jobs in 2015 2
... Medical Devices strengthened its executive team with the appointment ... Joseph Lee, Xeridiem Medical Devices, President said, "I am ... Medical Devices as Vice-President Business Development, effective March 1, ... design and development services with a focus on sales ...
... N.J., March 7, 2011 Ajinomoto Co., a ... and safe, effective nutraceutical solutions, has announced that ... granted federal trademark registration, (®), on the Principal ... Office.  The trademark is the latest milestone for ...
Cached Medicine Technology:Xeridiem Medical Devices Appoints Renae Moomjian, Vice President, Business Development 2Ajinomoto Co.'s Capsiate Natura® Reaches New Milestone 2
(Date:5/29/2015)... (PRWEB) May 29, 2015 Red Hot ... the newest Red Hot & Blue restaurant at 525 New ... Thursday, May 7, 2015. “The Red Hot & Blue Restaurant ... 18 years, but we have moved to a new location ... in the middle of all the activities on the Promenade–with ...
(Date:5/29/2015)... RIDGELAND, Miss. (PRWEB) May 29, 2015 ... recently announced the graduates of its Advanced Training ... trains students, who fill roles in their health ... both the theory and methodology of continuous quality ... is a sister-program to Dr. Brent James’ internationally ...
(Date:5/29/2015)... Inspire Nexus, a new social network officially launching ... many life coaches have asked, "How do I find ... to become a credentialed Coach?" , Many Life and ... long. Inspire Nexus, a social network for Coaches provides ... have experience coaching a certain number of hours, qualify ...
(Date:5/29/2015)... 29, 2015 The campaign focuses on ... a number of specific concerns within, including the importance ... mental health in the workplace. We are encouraged to ... campaign also brings special focus to people living with ... up and seek help from healthcare professionals and their ...
(Date:5/29/2015)... 2015 The report “Muscle Spasm ... on the therapeutic development for Muscle Spasm. Spasms ... the body, leading to many different symptoms and ... new targets and MOAs to produce first-in-class and ... review of Axillary Hyperhidrosis with 19 market data ...
Breaking Medicine News(10 mins):Health News:Red Hot & Blue Restaurant Opens in Cary, North Carolina 2Health News:Red Hot & Blue Restaurant Opens in Cary, North Carolina 3Health News:Red Hot & Blue Restaurant Opens in Cary, North Carolina 4Health News:HORNE LLP’s Healthcare Delivery Institute Graduates Class from the Advanced Training Program 2Health News:Mediaplanet Brings Activism to Those Living with Mental Illness in Bew “Mental Health Awareness” Campaign 2Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4
... parity insurance less likely to get timely outpatient care , , ... better share the burden of the cost for mental health ... up less of the bill, a new study says. , ... some of whose plans provided equal cost-sharing and others whose ...
... Clinical pharmacy services can significantly reduce the cost of ... care system, according to a new study by researchers ... every dollar spent by hospitals or health systems to ... drug costs, reductions in adverse drug events and medication ...
... , , TUESDAY, Dec. 23 (HealthDay News) -- As many ... States combine over-the-counter medications with prescription drugs in ways ... a new survey finds. , A recent report estimated ... emergency department visits for adverse drug reactions each year, ...
... and Human Services recently awarded Jefferson Hospital for Neuroscience ... organ donation conversion rate of 75 percent or greater ... given during the fourth National Learning Congress held in ... and staff at Jefferson Hospital for Neuroscience work tirelessly ...
... virtually a micro-camera, is a revolutionary diagnostic tool in diagnosing small ... GI tract, though the number of the images for the lesions ... reader still has to scan ten thousands of the images one ... lesions are in. So, it may be a big burden on ...
... of radiation therapy to treat cancer inevitably involves exposure ... have been well established, a number of patients experience ... These side effects related to inflammatory process cause discomfort ... treatment time. , A research article to be ...
Cached Medicine News:Health News:Psych Patients With Cost-Sharing Plans Use More Services 2Health News:Drug Combinations Putting Seniors at Risk 2Health News:Drug Combinations Putting Seniors at Risk 3Health News:Drug Combinations Putting Seniors at Risk 4Health News:Jefferson Hospital for Neuroscience receives Department of Health and Human Services award 2Health News:What is the mechanism of the chronic radiation enteritis? 2
The Oxoid Legionella Latex Test is a latex agglutination test for the identification of predominant Legionella species grown on plate media from patients with suspected Legionellosis or from environm...
... A revolutionary new agar plate for economically screening ... this biplate with the urine specimen. If the ... the chromogenic side of the biplate will 3 ... E. coli, the BluEcoli™ Urine Biplate is a ...
... The Trinity Biotech Captia™ Legionella ... (ELISA) is intended for the ... (IgG and IgM) to Legionella ... serum from patients with clinical ...
SDA is a patented isothermal amplification technology capable of generating billions of copies of target molecules from a single DNA or RNA template in just minutes....
Medicine Products: